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Abstract
Mortality is a well-recognized complication of Gram-negative bloodstream infection (BSI). The aim of this study was to develop a model to
predict mortality in patients with Gram-negative BSI by using the Pitt bacteraemia score (PBS) and other clinical and laboratory variables. A
cohort of 683 unique adult patients who were followed for at least 28 days after admission to Mayo Clinic Hospitals with Gram-negative BSI
from 1 January 2001 to 31 October 2006 and who received clinically predeﬁned appropriate empirical antimicrobial therapy was
retrospectively identiﬁed. Multivariable logistic regression was used to identify independent risk factors for 28-day all-cause mortality.
Regression coefﬁcients from a multivariable model were used to develop a risk score to predict mortality following Gram-negative BSI.
Malignancy (OR 3.48, 95% CI 1.94–6.22), liver cirrhosis (OR 5.42, 95% CI 2.52–11.65), source of BSI other than urinary tract or central
venous catheter infection (OR 5.54, 95% CI 2.42–12.69), and PBS (OR 1.98, 95% CI 0.92–4.25 for PBS of 2–3 and OR 6.42, 95% CI 3.11–
13.24 for PBS  4) were identiﬁed as independent risk factors for 28-day mortality in patients with Gram-negative BSI. A risk-score model
was created by adding points for each independent risk factor, and had a c-statistic of 0.84. Patients with risk scores of 0, 4, 8, 12 and 16 had
estimated 28-day mortality rates of approximately 0%, 3%, 14%, 45%, and 81%, respectively. The Gram-negative BSI risk score described
herein estimated mortality risk with high discrimination in patients with Gram-negative BSI who received clinically adequate empirical
antimicrobial therapy.
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Introduction
The outcome of patients with Gram-negative bloodstream
infection (BSI) depends on multiple host-related and pathogen-
related factors. Acute severity of illness scores, such as the
Acute Physiology and Chronic Health Evaluation (APACHE)
score, are mostly used in critically ill patients who are admitted
to intensive-care units (ICUs) [1]. However, the majority of
patients with Gram-negative BSI do not require ICU admission
[2]. Moreover, many of the variables used in such complex
scores are not pertinent to Gram-negative BSI. The Pitt
bacteraemia score (PBS), in contrast, has been used to stratify
patients with BSI according to acute severity of illness. It is a
simple score that is calculated at the time of initial patient
evaluation by using temperature (1 point for temperature of
35.1–36°C or 39.0–39.9°C and 2 points for temperature of
 35°C or  40°C), blood pressure (2 points for hypoten-
sion), mental status (1 point for disorientation, 2 points for
stupor, and 4 points for coma), and the presence or absence
of mechanical ventilation (2 points) and cardiac arrest
(4 points) [3,4]. The PBS has been recently described as being
superior to other acute severity of illness scores in predicting
the outcome of patients with sepsis [5]. However, clinical
variables other than acute severity of illness have been
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associated with mortality following Gram-negative BSI, such as
primary source of infection and patients’ underlying medical
conditions [6–13].
In this retrospective cohort study, clinical predictors of 28-
day all-cause mortality following Gram-negative BSI in adult
hospitalized patients were identiﬁed. The aim of the study was
to develop a scoring model with which to estimate the risk of
mortality following Gram-negative BSI by using the PBS and
other clinical and laboratory variables that were independently
associated with mortality.
Methods
Setting
The study was conducted at two Mayo Clinic hospitals: Saint
Mary’s Hospital and Rochester Methodist Hospital, located in
Rochester, Minnesota. Both are large tertiary-care hospitals
that combine to provide over 1950 licensed beds and care for
local residents as well as referral patients in a wide variety of
medical and surgical subspecialties.
Case deﬁnition
Gram-negative BSI was deﬁned as the growth of any aerobic
Gram-negative bacillus in a blood culture. The primary source
of BSI was deﬁned according to the CDC criteria [14].
Immunocompromised hosts were deﬁned as patients with any
of the following conditions: neutropenia, recent chemother-
apy, treatment with corticosteroids, human immunodeﬁciency
virus infection, recipients of solid organs or bone marrow
transplants, or recipients of other immunosuppressive medi-
cations. Patients with cancer were deﬁned as those with a
current diagnosis of malignant tumour, excluding skin basal and
squamous cell carcinoma.
Case ascertainment
A cohort of 708 patients with ﬁrst episodes of monomicrobial
Gram-negative BSI from 1 January 2001 to 31 October 2006
was retrospectively identiﬁed from the Mayo Clinic microbi-
ology laboratory database. The detailed case ascertainment
methods, as well as inclusion and exclusion criteria for
enrolment in this cohort, have been described previously [2].
Brieﬂy, we included adult patients  18 years of age with
ﬁrst episodes of monomicrobial BSI caused by aerobic Gram-
negative bacilli. Included patients were hospitalized at any medical
or surgical ﬂoor unit or ICU. All patients included in this cohort
received what was predeﬁned clinically as appropriate empirical
antimicrobial therapy for Gram-negative BSI within 24 h of
initial presentation. This included b-lactam antibiotics
with activity against aerobic Gram-negative bacilli, such as
b-lactam/b-lactamase inhibitors, third-generation and fourth-
generation cephalosporins, a monobactam, and carbapenems
with or without ﬂuoroquinolones. Aminoglycoside regimens
were excluded to avoid potential interaction with serum
creatinine.
Statistical analysis
The primary objective was to determine clinical predictors of
28-day all-cause mortality in patients with Gram-negative BSI.
We included in the analysis only patients who were followed
for at least 28 days from the onset of Gram-negative BSI
(n = 683). Patients who were lost to follow-up within 28 days
of BSI were excluded from the analysis (n = 25). Death was
conﬁrmed by reviewing medical records and the Minnesota
death registry database.
Multivariable logistic regression was used to analyse 28-day
mortality. The following variables were considered as candi-
date predictors of mortality: age, gender, diabetes mellitus,
congestive heart failure, chronic pulmonary disease, dementia,
end-stage renal disease, liver cirrhosis, malignancy, immuno-
compromised state, PBS, primary source of BSI, infection site
of acquisition, serum creatinine, and peripheral white blood
cell (WBC) count. The primary source of BSI was dichoto-
mized into urinary or central venous catheter (CVC)-related
vs. other sources of BSI. This was based on the results of
previous studies demonstrating that Gram-negative BSI
secondary to a urinary tract or CVC infection was associated
with better outcomes than BSI resulting from other sources of
infection [6–13].
The functional form of each of the continuous variables was
assessed. A generalized additive plot of the log odds of 28-day
mortality (logit of probability) against a smoothed version of
each continuous variable was used to gain a sense of linearity
of their relationship. A smoothing spline of four degrees of
freedom to characterize the continuous variable in the
generalized additive model producing the plot was used. The
ﬁnal functional form of the variable was then formally tested in
a logistic model.
To determine a ﬁnal multivariable model on which the risk
score would be based, bootstrap resampling was used. A
model was derived in each bootstrap sample by applying the
same backward model selection criteria (entry p <0.15 and
retention p <0.05) every time, thus accounting for uncertainty
in the model selection technique itself. The frequency of
selected variables was computed as a percentage across all 400
bootstrap samples. The ﬁnal multivariable prediction model
contained all variables that were individually retained in at least
70% of the bootstrap samples.
The probability of concordance, or c-statistic, was used to
quantify the discriminative ability of the ﬁnal multivariable
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logistic model. The c-statistic is equivalent to the area under a
receiver operating characteristic curve, with a value of 0.5
denoting random predictions and a value of 1.0 denoting
perfect predictions. To estimate the optimism bias from the
model selection process and then compute a bias-corrected c-
statistic, each bootstrap-selected model was examined on the
original data, and its performance was measured [15]. Bias was
estimated as the average difference in c-statistic values
between the bootstrap model and the test model, which was
then subtracted from the apparent concordance to obtain a
bias-corrected c-statistic. To visually assess calibration, deciles
of predicted risk were plotted from the model by the actual
fraction of patients who died within 28 days.
From the ﬁnal multivariable model, regression coefﬁcients
were used to derive a risk score for mortality. Points were
assigned for the presence of each risk factor in the ﬁnal
multivariable logistic model, and weighted approximately by the
corresponding regression coefﬁcients. For each risk factor, the
regression coefﬁcient was divided by the minimum absolute
value among all coefﬁcients in the ﬁnal multivariable model, and
subsequently multiplied by three. Predicted probabilities
obtained directly from the scoring model were plotted by risk
score values to visualize the estimated risk of mortality. All
analyses were carried out with the SAS statistical software
package (version 8.2; SAS Institute, Cary, NC, USA).
Results
The mean age  standard deviation of patients with Gram-
negative BSI was 64  17 years, and 60% (411/683) were
males. The overall 28-day mortality rate for Gram-negative BSI
in this cohort was 12% (85/683). The baseline clinical
characteristics of 28-day survivors and non-survivors are
shown in Table 1. Owing to skewed distributions, the natural
log transformation of serum creatinine was used, and periph-
eral WBC count was categorized, for all analyses.
From univariate logistic regression modelling, liver cirrhosis,
malignancy, a source of BSI other than the urinary tract or
CVC infection, PBS, serum creatinine and peripheral WBC
count were associated with a higher rate of 28-day mortality
(Table 1). These variables were subsequently included in a
multivariable regression analysis, and malignancy, liver cirrho-
sis, non-urinary/CVC source of infection, PBS and serum
creatinine were all identiﬁed as independent risk factors for
28-day mortality. The following variables were retained in at
least 70% of bootstrap samples, and thus deemed to be robust
prognostic factors for 28-day mortality: malignancy, liver
cirrhosis, non-urinary/CVC source of infection, and PBS. In
fact, each of these variables was selected in >95% of bootstrap
samples.
TABLE 1. Univariate logistic regression model results for risk factors for 28-day mortality in patients with Gram-negative
bloodstream infection
Variable Died within 28 days (n = 85) Alive at 28 days (n = 598) OR (95% CI) p-value
Age (years), mean  SD 65.7  15.8 64.2  16.7 1.01 (0.99–1.02) 0.43
Male gender, n (%) 53 (62) 358 (60) 1.11 (0.70–1.77) 0.66
Diabetes mellitus, n (%) 18 (21) 142 (24) 0.86 (0.50–1.50) 0.60
Congestive heart failure, n (%) 17 (20) 117 (20) 1.03 (0.58–1.82) 0.92
Chronic pulmonary disease, n (%) 15 (18) 108 (18) 0.97 (0.54–1.76) 0.93
Dementia, n (%) 1 (1) 13 (2) 0.54 (0.07–4.15) 0.55
End-stage renal disease, n (%) 6 (7) 18 (3) 2.45 (0.94–6.35) 0.07
Liver cirrhosis, n (%) 18 (21) 30 (5) 5.09 (2.69–9.62) <0.001
Malignancy, n (%) 59 (69) 256 (43) 3.03 (1.86–4.94) <0.001
Immunocompromised host, n (%) 34 (40) 196 (33) 1.37 (0.86–2.18) 0.19
Pitt bacteraemia score, n (%) <0.001
0 12 (14) 179 (30) 1.0 (reference)
1 5 (6) 133 (22) 0.56 (0.19–1.63) 0.29
2–3 23 (27) 159 (27) 2.16 (1.04–4.48) 0.04
 4 44 (52) 122 (20) 5.38 (2.73–10.60) <0.001
Source of BSI other than urinary tract/CVC, n (%) 78 (92) 356 (60) 7.57 (3.44–16.69) <0.001
Site of infection acquisition, n (%) 0.22
Healthcare-associated 31 (36) 210 (35) 1.0 (reference)
Community-acquired 18 (21) 178 (30) 0.69 (0.37–1.27) 0.23
Nosocomial 36 (42) 210 (35) 1.16 (0.69–1.95) 0.57
Serum creatininea (mg/dL), median (IQR) 1.6 (1.2–2.4) 1.3 (1.0–1.8) 1.81 (1.17–2.80) 0.007
Peripheral WBC counta (103/lL), median (IQR) 10.6 (3.5–20.3) 12.0 (5.7–16.7) 1.06 (0.90–1.25) 0.51
Peripheral WBC count categories (103/lL), n (%) 0.22
0–5 27 (32) 132 (22) 1.0 (reference)
5–15 26 (31) 266 (44) 0.48 (0.27–0.85) 0.01
15–20 9 (11) 105 (18) 0.42 (0.19–0.93) 0.03
>20 23 (27) 95 (16) 1.18 (0.64–2.19) 0.59
Time to start of antibiotics (days), mean  SD 0.3  0.4 0.3  0.4 0.97 (0.51–1.83) 0.93
Inappropriate antibiotic therapy, n (%) 2 (2) 7 (1) 2.06 (0.42–10.07) 0.37
BSI, bloodstream infection; CVC, central venous catheter; IQR, interquartile range; SD, standard deviation; WBC, white blood cell.
aLog-transformed values used to satisfy the regression assumption of normality.
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A multivariable logistic model that contained only variables
that were retained in the ﬁnal model after bootstrap sampling
had an apparent c-statistic of 0.84 (Table 2). The correspond-
ing bias-corrected c-statistic was 0.81. Model calibration
looked satisfactory, as the observed outcomes appeared to
be fairly close to the predictions (Fig. 1).
To derive a risk score for 28-day mortality, points were
assigned for each variable in the ﬁnal multivariable model,
weighted approximately by the corresponding regression
coefﬁcients (Table 2). A subject’s risk score is the cumulative
number of points from their risk proﬁle, and ranges in value
from 0 to 16. Fig. 2 compares the receiver operating
characteristic curves for the multivariable logistic regression
and simpliﬁed risk-score models, and shows that the simpliﬁed
risk score (c-statistic of 0.84) adequately summarizes the
multivariable logistic regression model.
The risk score provides clinicians with a simple tool with
which to estimate the risk of 28-day mortality in patients with
Gram-negative BSI (Fig. 3). A higher score corresponds to an
increased risk of mortality. For example, patients with risk
scores of  4 have a relatively low estimated mortality rate of
 3%. The estimated risk of mortality increases sharply for
risk scores of >8 with wider 95% CIs, which is reﬂective of
fewer numbers of subjects with increased risk.
Discussion
The proposed Gram-negative BSI risk score estimates the risk
of mortality in patients with Gram-negative BSI who receive
timely empirical antimicrobial therapy that is considered to be
clinically adequate for the treatment of Gram-negative BSI. The
score is based on variables that are independently associated
with mortality and include PBS, source of infection, and the
presence or absence of malignancy and liver cirrhosis.
TABLE 2. Final multivariable logistic regression model
results for predictors of 28-day mortality in patients with
Gram-negative bloodstream infection and risk-score point
allocation for each variable
Variable OR (95% CI) p-value
Scoring
points
Malignancy 3.48 (1.94–6.22) <0.001 3
Liver cirrhosis 5.42 (2.52–11.65) <0.001 4
Non-urinary/CVC source of BSI 5.54 (2.42–12.69) <0.001 4
Pitt bacteraemia score
0 1.0 (reference) 0
1 0.64 (0.21–1.90) 0.42 0
2–3
1.98 (0.92–4.25) 0.08 2
 4 6.42 (3.11–13.24) <0.001 5
BSI, bloodstream infection; CVC, central venous catheter.
Final multivariable model c-statistic = 0.84 (bias-corrected c-statistic = 0.81).
Risk-score model c-statistic = 0.84.
FIG. 1. Calibration plot of ﬁnal multivariable logistic model for
predictors of 28-day mortality in Gram-negative bloodstream infection.
Note: The observed frequency of 28-day mortality plotted by deciles of
predicted probability from the original (grey ﬁlled circles, error bars, and
dashed-line loess curve) and bootstrap/bias-corrected (blackXmarkers,
error bars and solid-line loess curve) modelling. Perfect calibration is
represented by the Y = X line.
FIG. 2. Receiver operating characteristic plot of the ﬁnal multivar-
iable logistic model and risk-score model of 28-day mortality for
Gram-negative bloodstream infection. Note: c-Statistic for both ﬁnal
multivariable logistic and risk-score models = 0.84
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The PBS was a highly signiﬁcant predictor of mortality in
patients with Gram-negative BSI. This observation is consistent
with the results of a recent investigation [5]. In this study, we
used a more sensitive categorization of the PBS (0–1 vs. 2–3 vs.
 4) rather than dichotomization of <4 and  4 as in previous
studies [4,16]. However, the PBS lacks some parameters that
are related to outcomes in patients with Gram-negative BSI,
such as primary source of infection. The current study
demonstrated that a source of BSI other than urinary tract
or CVC was independently associated with higher risk of
mortality. Establishing a source of infection at the time of initial
presentation may be challenging in some patients, especially
those with a gastrointestinal or respiratory source of infection
that may require imaging studies or further clinical samples to
be submitted for culture. However, a urinary tract source of
BSI may be established at the time of initial presentation on the
basis of urinary symptoms, urinalysis, and urine Gram-stain
results. Similarly, a CVC-related BSI can be supported by a
differential ‘time to positivity’ of >2 h between simultaneous
blood cultures obtained through a CVC and peripheral vein in
the absence of other apparent foci of infection [17]. As the
model dichotomizes the source of infection into urinary/CVC
vs. others, the risk score may be applied prior to establishing
the source of infection in some patients. For example, a patient
without a CVC who has no urinary symptoms and unremark-
able urinalysis ﬁndings probably has a source of infection other
than the urinary tract or CVC infection. In other cases where
the source of infection is not apparent at the time of initial
presentation, a range of mortality risk may be estimated from
the risk-score model with and without the allocated points for
the source of infection.
The association between cancer and mortality in patients
with Gram-negative BSI is congruous with ﬁndings from other
studies [18,19]. This is probably related to the immunocom-
promised status that typically occurs as a result of malignancy or
its treatment and the effects of cancer on survival. In addition,
the association between liver cirrhosis and mortality in patients
with BSI has been recently described in three large studies [20–
22]. It is conceivable that patients with liver cirrhosis have a
poor prognosis with Gram-negative BSI. Liver cirrhosis is
associated with a relatively low neutrophil count, neutrophil
dysfunction, and complement deﬁciency resulting from both
decreased production and increased consumption [23].
Delayed and inappropriate antimicrobial therapy are both
associated with mortality in patients with BSI [7,24]. As
antimicrobial susceptibility results are not available at the time
of initial presentation, our model was designed to eliminate
upfront the majority of patients who received delayed or
inappropriate antimicrobial therapy. All patients included in
this cohort received antimicrobial regimens that were consid-
ered to be acceptable for the empirical treatment of Gram-
negative BSI within 24 h of presentation [25]. As a result, the
timing and choice of antimicrobial regimen did not appear to
inﬂuence the model results, as most patients received early
and appropriate antimicrobial therapy (Table 1).
As the derivation cohort for the Gram-negative BSI risk
score was a referral rather than a population-based cohort,
patients >80 years of age were under-represented, as previ-
ously demonstrated [26]. This is probably the explanation for
the lack of an age effect on mortality in this study. Additionally,
the prevalence rates of liver cirrhosis and cancer are probably
higher in referral than in population-based cohorts. Therefore,
FIG. 3. Predicted probability of 28-day
mortality in patients with gram-negative
bloodstream infection by risk score. Note:
Vertical lines represent 95% CIs. The size
of marker for point estimates is weighted
approximately by the number of subjects
with a corresponding risk score.
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the model should be externally validated in a population-based
cohort with a fair representation of elderly patients and a
lower prevalence of liver cirrhosis and malignancy.
The overall 28-day all-cause mortality rate of 12% in
patients with Gram-negative BSI in this study was similar to the
reported mortality rates in recently published population-
based studies [11,27]. However, the mortality rate in this study
was markedly lower than that previously reported from
studies of Gram-negative BSI performed during the prior two
decades [10,28]. Identifying independent risk factors for
mortality in patients with Gram-negative BSI in the current
era of advanced critical care and antimicrobial management
provides a distinct advantage, and ensures that the model
results are applicable to current clinical practice.
The study has some limitations. First, this was a retrospec-
tive cohort study, so clinical variables, including PBS, were
collected retrospectively. Second, our cohort included patients
hospitalized at tertiary-care facilities, rather than being a
population-based cohort; therefore, the results may be
affected by referral bias. Despite the possible selection bias
resulting from excluding 25 subjects with insufﬁcient follow-up,
a post hoc analysis comparing excluded subjects with those
included in the analysis showed no signiﬁcant differences in
demographic or clinical characteristics (results not shown).
Finally, the study enrolled only adult patients; therefore, the
results should not be extrapolated to children.
In summary, the risk of mortality in patients with Gram-
negative BSI can be estimated by using a risk score derived
from acute severity of illness as estimated by the PBS, clinical
manifestations (primary source of BSI), and underlying
medical conditions such as cancer and liver cirrhosis. The
score is applicable to patients with Gram-negative BSI who
are treated properly with clinically acceptable empirical
antimicrobial regimens. This Gram-negative BSI risk score
provides treating physicians with the tools to answer one of
the most difﬁcult questions asked by patients and their
families at the time of initial presentation with Gram-negative
BSI: what is the estimated risk of mortality? The Gram-
negative BSI risk score may also have utility in future clinical
research investigations.
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